Abstract: A combination of 2-acetoxy-5-(&agr;-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine or a pharmaceutically acceptable salt thereof, and aspirin, which possess excellent inhibitory activity against platelet aggregation and thrombogenesis, and is useful for preventing or treating diseases caused by thrombus or embolus.

Abstract: Use for the treatment of diseases having an inflammatory basis of compounds or salts thereof, having the following general formula (I): A-Xt-L-(W)p—NO2 wherein A contains the radical of a drug, Xt and W arc bivalent radicals, L, is a covalent bond or oxygen, sulphur, NRtc wherein Rtc is H or a C1-C5 linear or branched alkyl.

Abstract: The invention pertains to methods for treating medical disorders characterized by elevated levels or abnormal expression of IL-1 by administering an IL-1 antagonist, such as soluble type II IL-receptor.

Abstract: The invention relates to medicine. The inventive composition comprises a non-steroid anti-inflammatory agent and at least one compound potentiating a pharmaceutical action, decreasing the toxicity and side effects thereof. The amplifying composition is selected from diocarbonillic acids or salts thereof, amino acids or salts thereof, vitamins, poliphenolic compounds or products of animal and/or vegetable origin, containing the compound. The inventive composition comprises also a special additive agent representing a carbohydrate and/or sorbing agent. The inventive composition is characterized by a better expressed pharmacological action and low toxicity even during a long period of use.

Abstract: The present invention provides methods of preventing, treating or ameliorating one or more symptoms of disorders in which modulation of a subject's immune system is beneficial utilizing a lymphoid tissue inducing agent and an immunomodulatory agent. In particular, the present invention provides methods of preventing, treating or ameliorating a proliferative disorder, an infectious disease, a cardiovascular disease, an autoimmune disorder, or an inflammatory disorder or one or more symptoms thereof comprising administering to a subject in need thereof one or more lymphoid tissue inducing agents and one or immunomodulatory agents. The present invention also provides compositions and articles of manufacture for use in preventing, treating or ameliorating one or more symptoms associated with disorders in which modulation of a subject's immune system is beneficial, including, but not limited to proliferative disorders, infectious diseases, cardiovascular diseases, autoimmune disorders and inflammatory disorders.

Abstract: The invention relates to the use of &agr;-lipoic acid in reduced or oxidized form or derivatives thereof with intact dithiolane structure in the form of enantiomers or pharmaceutically acceptable salts, amides, esters, thioesters, ethers or metabolites for the adjuvant therapy of dementias.

Abstract: The present invention relates to compositions and methods for treating immune system diseases such as rheumatic disease, by administering to a subject soluble CTLA4 molecules that block endogenous B7 molecules from binding their ligands, alone, or in conjunction with other agents including Disease Modifying Anti-Rheumatic Drugs (DMARDs).

Abstract: A topical composition for use in a variety of environments includes an active component, e.g., acetylsalicylic acid, a solvent mixture for the active components and, optionally, a silicone additive. The topical compositions according to the invention include nail hardeners, deodorants and sunscreen products.

Abstract: A pharmaceutically delivery system is described comprising a pharmaceutically active agent and acidified nitrite as an agent to produce local production of nitric oxide at the skin surface. The dosage form may be in any pharmaceutically acceptable carrier means and comprises an acidifying agent adapted to reduce the pH at the environment. In one embodiment, a barrier consisting of a membrane allows diffusions of the anaesthetic and nitrite ions while preventing direct contact of the skin and acidifying agent.

Abstract: This invention relates to a composition and method for the treatment of white line disease, including ailments such as Onychomycosis, sporotichosis, hoof rot, jungle rot, pseudallecheria boydii, scopulariopsis or athletes foot. The composition of the present invention is useful for the treatment of fungal infections such as Onychomycosis in warm blooded animals such as humans and horses. The method of the present invention is directed to the application of a therapeutic amount of the present composition.

Abstract: This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit phosphodiesterase inhibiton, growth inhibition and apoptosis induction, but prefereably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.

Abstract: Skin-growth-enhancing compounds and compositions including a therapeutically effective amount of at least one electron active compound, or a pharmaceutically acceptable derivative thereof, that has at least two polyvalent cations, at least one of which has a first valence state and at least one of which has a second, different valence state. Preferred compounds include Bi(III,V) oxide, Co(II,III) oxide, Cu(I,III) oxide, Fe(II,III) oxide, Mn(II,III) oxide, and Pr(III,IV) oxide, and Ag(I,III) oxide, or a combination thereof. These compounds may be in a crystalline state having metallic cations of two different valences, or electronic states, in the inorganic crystal. Also included are articles containing such compositions, such as wound dressings, and methods for facilitating or enhancing skin growth using these compounds, compositions, and articles, such as for the treatment or management of burns or skin grafts.

Abstract: A composition and method of treating fever, and optionally treating pain, is disclosed. The composition and method utilize a nonopioid analgesic and an endothelin antagonist as active agents to treat fever in mammals, including humans. The composition also is useful in the prevention and treatment of stroke and other cardiovascular disorders, like myocardial infarction.

Abstract: Monoclonal antibodies directed against coagulation factors and their use in inhibiting thrombosis are disclosed.

Abstract: A composition is provided that is suitable for topical administration for the treatment of a skin irritation, the composition comprising acetylsalicylic acid and sodium bicarbonate. Also provided is a method for treating a skin irritation in an individual comprising topically administering to the affected area a therapeutically effective amount of a composition comprising acetylsalicylic acid and sodium bicarbonate. The composition is particularly useful for decreasing the temperature at the surface of a sunburn and for reducing pain and discomfort caused by a sunburn.

Abstract: The invention relates to the isolation of novel cyclooxygenase type 1 (COX-1) variant enzymes. More specifically, the invention relates to the identification of cyclooxygenase transcripts harboring inton 1, or fragment thereof, of cyclooxygenase 1. The invention further relates to the diagnosis of aberrant cyclooxygenase type 1 variant gene or gene product; the identification, production, and use of compounds which modulate cyclooxygenase type 1 variant gene expression or the activity of the cyclooxygenase type 1 variant gene product including but not limited to nucleic acid encoding cyclooxygenase type 1 variants and homologues, analogues, and deletions thereof, as well as antisense, ribozyme, triple helix, antibody, and polypeptide molecules as well as small inorganic molecules; and pharmaceutical formulations and routes of administration for such compounds.

Abstract: Compositions and methods for vaginal, buccal or nasal transmucosal delivery of drugs and for cryoprotecting of cells and embryos. For cryoprotection, the composition consisting essentially consist of a non-ionizable glycol derivative. For transmucosal delivery, the compositions essentially consist of a non-ionizable glycol derivative in a combination with a pharmaceutically active agent. For transmucosal delivery, the non-ionizable glycol derivative may be further combined with a mucoadhesive agent and/or a penetration enhancer and/or lipophilic or hydrophilic carrier for adhesion to and transport through a mucosa. The compositions are particularly suitable for administration of drugs through a nasal, buccal and vaginal mucosa or for long-term preservation of cell or embryos.

Abstract: A consumable film adapted to adhere to and dissolve in the oral cavity of a warm-blooded animal including humans, comprising at least one water soluble polymer, a taste masking effective amount of a sweetener, and a pharmaceutically active agent having a sufficiently unpleasant taste that it is desirably masked by the sweetener.

Abstract: This invention relates to treating an inflammatory disease by administering a phosphodiesterase 4 inhibitor in combiantion with an inhibitor of prostaglandin synthesis, NSAIDs being exemplary.

Abstract: A solid dosage form for oral administration to a patient comprising a core tablet sheathed in an annular body of compressed powder or granular material is provided. A preferred embodiment of the solid dosage form reduces contact of the active ingredient in solid form with the mucosa lining the gastrointestinal tract, which is particularly advantageous for delivering an ulcerative drug. A tool set comprising a columnar punch and a punch assembly comprising an annular punch and core rod, and a tableting process for making the solid dosage form are also provided.

Abstract: This invention is a safe and effective composition and method for treating acute migraine attacks using pseudoephedrine, acetaminophen, and other agents in an orally administrated form to alleviate the pain and cluster of symptoms characteristic of migraine attacks such as nausea, photophobia, phonophobia, and functional disabilities as well as the prodrome phase of a migraine attack.

Abstract: Implantable, injectable, insertable, or otherwise administrable compositions that form hydrogels when implanted, injected, inserted, or administered into or onto living tissues comprise a pharmaceutically effective compound wherein the pharmaceutically effective compound is a codrug, or pharmaceutically acceptable salt or prodrug thereof in admixture with a hydrogel-forming compound. The pharmaceutically effective compound may be any compound that is soluble in bodily fluids, or that forms bodily fluid-soluble adducts when exposed to bodily fluids. Exemplary compounds include analgesic, anti-inflammatory and antibiotic compounds. The hydrogel-forming compound is a biologically tolerated substance that forms a hydrogel upon exposure to bodily fluids, such as the interstitial fluid surrounding or within a joint.

Abstract: The present invention provides pharmaceutical compositions of acetylsalicylic acid and omega-3 oils which enable safe and stable oral administration within the range of the narrow therapeutic index prescribed for the prevention of alterations of the cardiovascular system.

Abstract: An extended release analgesic for controlling pain comprised of an opioid or non-opioid analgesic drug ionically bound to hyaluronic acid, poly-&ggr;-glutamic acid or other ionic polymers, and injected into a body either subcutaneously, intramuscularly or intraperitoneally, utilizing counter-ions of different valences to control the rate of release into the body.

Abstract: The invention relates to the use of ambroxol and the pharmacologically acceptable salts thereof for preparing a pharmaceutical composition for the treatment of diseases which are based on a powerful activation of voltage-dependent sodium channels, particularly for the treatment of chronic pain.

Abstract: The invention concerns a pharmaceutical composition for transdermal administration comprising: a polymeric release matrix capable of forming a soft film after drying, selected among cellulose polymers or copolymers, said matrix being present at a concentration not exceeding 6% of the composition weight; an active principle selected among the group of non-steroid anti-inflammatory agents comprising at least a metal carboxylic or carboxitate group; a transcutaneous absorption promoter of the active principle; water; and at least a physiologically acceptable non-aqueous solvent capable of dissolving the release matrix, the active principle and transcutaneous absorption promoter and to be rapidly eliminated by evaporation in contact with the skin.

Abstract: The invention concerns anti-tissue factor (anti-TF) antibodies with enhanced anticoagulant potency, and methods and means for identifying, producing and using such antibodies. The anti-TF antibodies of the present invention are designed to bind to an epitope comprising the C-terminal macromolecular substrate binding region of TF. The invention also concerns methods of treating TF-VIIa related diseases or disorders comprising administering anti-TF antibodies alone or in combination with at least one additional anticoagulant and/or anti-platelet agent.

Abstract: Disclosed herein are chemopreventive methods and topical formulations for the prevention and treatment of ultraviolet light-induced skin cancers, pre-cancerous lesions, and hyperproliferative disorders in mammals, such as humans, utilizing doses of non-steroidal anti-inflammatory drugs. Low doses of non-steroidal anti-inflammatory drugs are present in the topical formulations and allow continued regular use over an extended period of time to prevent such disorders. In particular, the present invention is particularly suitable for non-melanoma skin cancers as these cancers tend to appear in areas of the skin that have had excess sun exposure (head, neck and arms) meaning that the chemopreventive agent would not need to be applied over the entire body of the typical patient. Moreover, it is possible to identify “high-risk” individuals within the populations because people who report one episode of NMSC tend to have a high incidence of a subsequent episode.

Abstract: A composition for the treatment and prevention of endothelial dysfunction comprising a therapeutically effective amount of anti-inflammatory agents comprising; acetylsalicylic acid, an amino sugar and a zinc compound.

Abstract: The present invention discloses a new use of NO-releasing NSAIDs, especially NO-releasing NSAIDs of the formula I, or a pharmaceutically acceptable salt or enantiomer thereof, for the manufacture of a medicament for the treatment of bacterial infections, especially caused or mediated by Helicobacter pylon. Disclosed is also the new use of a NO-releasing NSAID in combination with an acid susceptible proton pump inhibitor for the treatment of bacterial infections.

Abstract: External preparations for allergic dermatitis containing Aspirin alone as the active ingredient, which exert an excellent therapeutic effects on allergic dermatitis with lower side effects; and a method for treating allergic dermatitis by using these agents for external use.

Abstract: Disclosed are unique methods for identifying the lowest, yet optimal, aspirin doses for patients. These methods are also characterized as having little to no aspirin-related side-effects. These methods may be used pre-as well as post-thrombotic event, and employs a patient's urinary thromboxane B2 metabolic levels (e.g., 11-dehydrothromboxane B2), to identify the patient's platelet activation level. A patient's urinary thromboxane B2 metabolic level is then used to calculate and appropriate and individualized treatment effective for utilizing platelet activation. Kits for utilizing this technique are also provided. In yet another particular aspect, the invention provides a method for utilizing a random urine sample obtained from a patient to determine whether a patient or particular individual's current dosage of aspirin is providing an adequate and appropriate level of inhibition of platelet activation levels, as compared to inhibition levels observed in individuals not taking aspirin.

Abstract: External preparations for treating pruritus containing Aspirin as an active ingredient, which exert an excellent therapeutic effects on pruritus with less side effects.

Abstract: The present invention involves methods and reagents for diagnosing and treating glaucoma and related disorders. Specifically, the invention relates to a method of identifying mutations in the TIGR gene of a glaucomatous patient and treating them with an effective amount of a non-steroidal anti-inflammatory drug. Additionally the invention allows the identification of individuals at risk for progressive increases in intraocular pressure, which is a risk factor for glaucoma; the invention thus also allows the identification of individuals among ocular hypertensive/glaucoma suspect groups at increased risk of visual field loss.

Abstract: This invention provides novel methods for improving plant quality and yield in the presence of pathogens. The method increases the levels of pathogenesis-related proteins, such as PR1, phenylalanine ammonia lyase, or plant cell wall proteins such as hydroxyproline-rich glycoproteins, in a plant by contacting the plant with a plant systemic inducer and a reactive oxygen species wherein the amount of the reactive oxygen species is sufficient to increase the amount of the pathogenesis-related protein above the level induced by the plant systemic inducer in the absence of the reactive oxygen species. A preferred reactive oxygen species is peracetic acid; a preferred plant systemic inducer is salicylic acid.

Abstract: The invention relates to a pharmaceutical composition for relieving pelvic pain or infertility associated with uterine dysrhythmia. The composition includes a locally-administered anti-dysrhythmic treating agent and a bioadhesive extended-release carrier. The composition may be delivered in an extended release formulation that includes a bioadhesive, water-swellable, water-insoluble, cross-linked polycarboxylic acid polymer, such as polycarbophil. The treating agent may be a local anesthetic, such as lidocaine. The invention also relates to a method of treating or preventing pelvic pain, or treating or improving infertility, by inserting a mixture of an anti-dysrhythmic treating agent and a bioadhesive carrier into the vagina of the patient to be treated.

Abstract: Biologically active extracts of celery seed are produced by controlled ethanolic extraction, distillation and drying, and further processing by supercritical fluid extractions (SFE), and may be further fractionated by column fractionation, distillation, LiAlH reduction and the like. These extracts possess activity for the treatment and prevention of acute and chronic pain, inflammation and gastrointestinal irritation.

Abstract: The invention is based on evidence that the anti-neoplastic effects of high dose NSAID treatments involve a complex pathway which involves alterations in the expression of genes which regulate a number of biological processes. The invention allows a more accurate molecular picture of cancer response to NSAIDS, and in so doing, allows one to assess the efficacy of a particular NSAID on a particular cancer, and to screen NSAIDS, and drugs generally, for their ability to produce NSAID-like anti-neoplastic effects.

Abstract: A method and a pharmaceutical composition for inhibiting premature rupture of the fetal membranes, ripening of the uterine cervix and preterm labor of female mammals including human. The method includes the step of administering compounds for reversing at least two biochemical conditions being associated with the above processes. The pharmaceutical composition includes compounds for reversing at least two biochemical conditions being associated with the above processes.

Abstract: An orally administrable pharmaceutical formulation is provided that combines, as active agents, a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, aspirin, and optionally at least one of vitamin B6, B12, and folate; the active agents are each present in a unit dose appropriate for once-daily dosing, and at least one of the active agents is contained in a dosage unit within the dosage form that physically separates it from the other active agents. The formulation is provided as a simple and convenient therapy to reduce the risk of cardiovascular events in individuals who are at elevated cardiovascular risk, including individuals who have systemic lupus erythematosus. The formulation is also therapeutic for individuals during or immediately following an occurrence of acute myocardial infarction.

Abstract: Compositions and methods are provided for activation of endogenous plant pathogen resistance pathways, including systemic acquired resistance, the hypersensitive reaction response and the upregulation of pathogenesis related proteins. The compositions comprise as active agents one or more naturally occurring compounds or essential oils selected from cedar oil, cinnamon oil, grapefruit oil, grapefruit seed extract oil, ferulic acid and acetyl salicylic acid. The methods involve directly applying formulations comprising one or more of these active agents to a Gymnosperm to induce endogenous plant defense pathways as a therapeutic or prophylactic treatment against fungal pathogens such as pitch canker and white pine blister rust.

Abstract: The present invention relates to the discovery of a transdermal delivery system that can deliver high molecular weight pharmaceuticals and cosmetic agents to skin cells. A novel transdermal delivery system with therapeutic and cosmetic application and methods of use of the foregoing is disclosed.

Abstract: The invention provides a method of treating a mammal having, or at risk of, an indication associated with a TGF-beta deficiency comprising administering one or more agents that is effective to elevate the level of TGF-beta. The invention also provides novel compounds that elevate TGF-beta levels, as well as pharmaceutical compositions comprising compounds that elevate TGF-beta levels, and methods for detecting diseases associated with endothelial cell activation.

Abstract: The present invention is directed to coadministration of the fibrinogen receptor antagonists 3S-[[4-[[4-aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoic acid or ethyl 3S-[[4-[[4-(aminoiminomethyl)phenyl]amino]-1,4-dioxobutyl]amino]-4-pentynoate together with an anti-platelet agent such as aspirin and/or an anti-coagulant such as heparin.

Abstract: A composition for delivery of a medicament that has a bitter taste and/or causes throat catch is provided. The composition contains Carbomer 934, Carbomer 971, Carbomer 974, PEG-5M or a mixture thereof in an amount sufficient to mask the bitter taste of the medicament and/or throat catch.

Abstract: The invention relates to the use of cocoa procyanidins in combination with an aspirin as an anti-platelet therapy and compositions comprising cocoa procyanidins and aspirin (acetylsalicyclic acid).

Abstract: Described are methods of promoting improvement of skin condition by administering a turmeric component and glycolic acid to a patient afflicted with a skin disorder.

Abstract: The invention provides a method for treating, preventing, or reducing the risk of developing a condition selected from the group consisting of acute coronary ischemic syndrome, thrombosis, thromboembolism, thrombotic occlusion and reocclusion, restenosis, transient ischemic attack, and first or subsequent thrombotic stroke, in a patient, comprising administering to the patient a therapeutically effective amount of an antiplatelet agent in combination with a therapeutically effective amount of a COX-2 inhibitor. The invention also provides a pharmaceutical composition comprising a therapeutically effective amount of a COX-2 inhibitor, or a pharmaceutically acceptable salt thereof, and an antiplatelet agent, or a pharmaceutically acceptable salt thereof.

Abstract: The use of acetylsalicylic acid for the treatment of migraine and other serotonin-dependent, platelet-mediated disorders is characterized in that the active ingredient is administered with the aid of a transdermal therapeutic system (TTS).

Abstract: A topical composition for use in a variety of environments includes an active component, e.g., acetylsalicylic acid, a solvent mixture for the active components and, optionally, a silicone additive. The topical compositions according to the invention include nail hardeners, deodorants and sunscreen products.